Abzena to Work with to Produce IMM-BCP-01 for Clinical Testing

Pharma Tech Outlook: Pharma Tech Magazine

Abzena to Work with to Produce IMM-BCP-01 for Clinical Testing

By Pharma Tech Outlook | Tuesday, February 16, 2021

Abzena has been selected to work with Immunome to produce IMM-BCP-01 for clinical testing - a therapeutic antibody cocktail to treat COVID-19.

FREMONT, CA: Immunome, a biopharmaceutical firm utilizing a proprietary human memory B cell platform to develop antibody therapeutics, and Abzena, a partner research firm for integrated discovery to cGMP manufacturing offerings for biologics, announces that Abzena was chosen as Immunomes partner research firm for IMM-BCP-01, an investigational therapeutic antibody cocktail for COVID-19 being developed to target multiple SARS-CoV-2 antigens. Abzena will work with Immunome to generate the antibody cocktail for clinical testing. Immunome secured a $13.3 million agreement run by the United States Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, in partnership with the Defense Health Agency, to support this program.

Immunome has utilized an innovative biologics research platform to perform large-scale B cell interrogation of COVID-19 super-responders to find suitable antibodies. The Immunome teams are visionary scientists and pioneers in the field, and the company is honored to have been chosen as the service provider for clinical good manufacturing practice (GMP) manufacturing of the Immunome antibody cocktail. It strongly believes in this agent's potential clinical advantage and looks forward to assisting patients in requirement.

Immunome was selected Abzena as the Contract Development and Manufacturing Organization (CDMO) partner due to scientific expertise, flexibility, and potential to execute on our timeline, vital in these times when a rapid response to the pandemic is needed. The company is excited that Jonathan and his team share a passion for science and offering high-quality patient outcomes. It hopes to positively affect the landscape of the global pandemic through the new antibody-based therapeutic approach.

Immunome is a biopharmaceutical firm utilizing the proprietary human memory B cell platform to develop first-in-class antibody therapeutics tailored to change the way diseases are presently being treated with an initial focus on oncology and infectious diseases, comprising COVID-19. Immunomes proprietary discovery platform finds novel therapeutic antibodies and their targets by using highly educated components of the immune system, memory B cells, to battle their disease.

Weekly Brief


Read Also